Amphastar Pharmaceuticals (FRA:29A) EV-to-EBIT : 10.67 (As of May. 15, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Amphastar Pharmaceuticals EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Amphastar Pharmaceuticals's Enterprise Value is €2,184.0 Mil. Amphastar Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €204.6 Mil. Therefore, Amphastar Pharmaceuticals's EV-to-EBIT for today is 10.67.

The historical rank and industry rank for Amphastar Pharmaceuticals's EV-to-EBIT or its related term are showing as below:

FRA:29A' s EV-to-EBIT Range Over the Past 10 Years
Min: -2976.06 Med: 15.62 Max: 1078.03
Current: 10.64

During the past 13 years, the highest EV-to-EBIT of Amphastar Pharmaceuticals was 1078.03. The lowest was -2976.06. And the median was 15.62.

FRA:29A's EV-to-EBIT is ranked better than
72.41% of 667 companies
in the Drug Manufacturers industry
Industry Median: 17.74 vs FRA:29A: 10.64

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Amphastar Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2024 was €2,293.5 Mil. Amphastar Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €204.6 Mil. Amphastar Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 8.92%.

Amphastar Pharmaceuticals EV-to-EBIT Historical Data

The historical data trend for Amphastar Pharmaceuticals's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amphastar Pharmaceuticals EV-to-EBIT Chart

Amphastar Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

15.34

192.22

12.69

10.81

16.82

Amphastar Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial															14.01	23.43	13.59	16.82	11.23

Competitive Comparison of Amphastar Pharmaceuticals's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Amphastar Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amphastar Pharmaceuticals's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amphastar Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Amphastar Pharmaceuticals's EV-to-EBIT falls into.

Amphastar Pharmaceuticals EV-to-EBIT Calculation

Amphastar Pharmaceuticals's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	2184.017	/	204.626
	=	10.67

Amphastar Pharmaceuticals's current Enterprise Value is €2,184.0 Mil.
Amphastar Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €204.6 Mil.

Amphastar Pharmaceuticals (FRA:29A) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Amphastar Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 )	=	EBIT	/	Enterprise Value (Q: Mar. 2024 )
	=	204.626	/	2293.51178
	=	8.92 %

Amphastar Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2024 was €2,293.5 Mil.
Amphastar Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €204.6 Mil.

Amphastar Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Amphastar Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Amphastar Pharmaceuticals (FRA:29A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amphastar Pharmaceuticals Inc (FRA:29A) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

AMPH:USA 29A:Germany

Address

11570 6th Street, Rancho Cucamonga, CA, USA, 91730

Website

http://www.amphastar.com

Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.

Amphastar Pharmaceuticals (FRA:29A) Headlines

No Headlines